James Allison - Jounce Therapeutics Co-Founder
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Founder
Dr. James P. Allison, Ph.D. is a cofounder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of Tcell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the Tcell antigen receptor protein. His research led to the clinical development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial SloanKettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial SloanKettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the AAIDana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Dr. Allison recently received an AACRSU2CCRI cancer immunotherapy dream team grant, for which he will serve as the Dream Team leader
| Professional Marks | Ph.D |
| Phone | 857 259 3840 |
| Web | https://jouncetx.com |
James Allison Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Allison against Jounce Therapeutics stock is an integral part of due diligence when investing in Jounce Therapeutics. James Allison insider activity provides valuable insight into whether Jounce Therapeutics is net buyers or sellers over its current business cycle. Note, Jounce Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jounce Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Allison over a month ago Disposition of 1841 shares by James Allison of Insperity at 100.29 subject to Rule 16b-3 |
Jounce Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Jounce Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Jounce Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Jounce Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Jounce to invest in growth at high rates of return. When we think about Jounce Therapeutics' use of debt, we should always consider it together with cash and equity.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 137 people. Jounce Therapeutics (JNCE) is traded on NASDAQ Exchange in USA and employs 141 people. Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 |
Jounce Therapeutics Leadership Team
Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Drew MD, Founder | ||
| Barbara Duncan, Independent Director | ||
| Luis Diaz, Director | ||
| Robert Schreiber, Founder | ||
| Padmanee MD, Founder | ||
| Drew Pardoll, Co-Founder | ||
| Louis MD, Founder | ||
| Deborah Law, Chief Scientific Officer | ||
| Elizabeth MD, Chief Officer | ||
| Richard Murray, President CEO, Director | ||
| Kimberlee Drapkin, CFO, Treasurer | ||
| Robert Kamen, Independent Director | ||
| Hugh Cole, Chief Business Officer and Head of Corporate Development | ||
| Thomas Gajewski, Co-Founder | ||
| Elizabeth Trehu, Chief Medical Officer | ||
| Robert Tepper, Independent Director | ||
| Perry Karsen, Chairman of the Board | ||
| Padmanee Sharma, Co-Founder | ||
| Cary Pfeffer, Independent Director | ||
| Duncan Higgons, Independent Director | ||
| James Allison, Co-Founder |
Jounce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jounce Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jounce Therapeutics' short interest history, or implied volatility extrapolated from Jounce Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |